---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-076672"
form_type: "8-K"
ticker: "EMMA"
cik: "0000822370"
company_name: "Emmaus Life Sciences, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:46:33.933047+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Emmaus Life Sciences Q2 net revenue down 48% to $2.8M; net loss narrows to $1.1M

## Summary
- Net revenue $2.8M, down 48% YoY from $5.4M; competition from generic L-Glutamine cited.
- Loss from operations $0.4M vs income of $0.6M in prior year.
- Net loss $1.1M ($0.02/share) vs $2.2M ($0.03/share) in Q2 2024; decrease due to lower other expense.
- Cash balance $0.9M at June 30, 2025, down from $1.4M at year-end 2024.
- Operating expenses reduced 33% to $3.0M, primarily from headcount reduction in Q4 2024.

## SEC filing metadata
- accession: 0001213900-25-076672
- form_type: 8-K
- ticker: EMMA
- cik: 0000822370
- company_name: Emmaus Life Sciences, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/822370/000121390025076672/0001213900-25-076672-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/822370/000121390025076672/ea0253040-8k_emmaus.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-076672
- JSON: https://secwatch.observer/filing/0001213900-25-076672.json
- Plain text: https://secwatch.observer/filing/0001213900-25-076672.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.